Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Testosterone (TRT) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both HCG (Human Chorionic Gonadotropin) and Testosterone (TRT) have evidence — compare verdict strength side-by-side.
Prescription-only and indication-dependent. For fertility preservation / intratesticular-testosterone maintenance on TRT, small studies used ~125-500 IU subcutaneously every other day. For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No dietary-supplement dose exists.
any
Prescription hCG — recombinant (choriogonadotropin alfa) or urinary-derived, by injection
Prescription-only and clinician-directed — this is a controlled substance, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: TRT for diagnosed hypogonadism is titrated to a mid-normal testosterone level. Intramuscular testosterone esters (cypionate/enanthate) are commonly dosed around 50–100 mg weekly (or ~100–200 mg every 2 weeks); long-acting testosterone undecanoate is dosed less frequently. Transdermal gels (~50–100 mg/day applied) and subcutaneous injection are alternative routes. Supraphysiologic anabolic-steroid doses are far higher, illegal, and dangerous — not a regimen this library endorses.
any
Clinician-prescribed testosterone (intramuscular ester or transdermal gel) for diagnosed hypogonadism — controlled substance, prescription-only
Weeks
Months
Months
Within ~36 hours
Weeks to months
Months
Months
Throughout use
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
J Clin Endocrinol Metab (2005) · Rct · n=29
29 men with normal reproductive physiology randomized to weekly testosterone enanthate plus saline placebo or 125, 250, or 500 IU hCG every other day for 3 weeks
Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
J Urol (2013) · Observational · n=26
Retrospective cohort of 26 hypogonadal men on testosterone replacement plus 500 IU intramuscular hCG every other day, mean follow-up 6.2 months
A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.
Fertil Steril (2009) · Observational · n=100
Combined analysis of four Phase III open-label studies in 100 men with complete idiopathic or acquired hypogonadotropic hypogonadism, pretreated with hCG for 3-6 months then hCG plus recombinant FSH
Effects of Testosterone Treatment in Older Men.
The New England journal of medicine (2016) · Rct · n=790
The coordinated Testosterone Trials (TTrials) — seven randomized, double-blind, placebo-controlled trials in 790 men aged 65+ with confirmed low testosterone and symptoms, treated with testosterone gel for one year
Cardiovascular Safety of Testosterone-Replacement Therapy.
The New England journal of medicine (2023) · Rct · n=5246
TRAVERSE: a randomized, double-blind, placebo-controlled non-inferiority trial of transdermal testosterone in 5246 middle-aged and older hypogonadal men with high cardiovascular risk — the largest TRT cardiovascular-safety trial
Safety and Efficacy of Testosterone Therapy on Musculoskeletal Health and Clinical Outcomes in Men: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Endocrine practice (2023) · Meta analysis
Systematic review and meta-analysis of 16 randomized placebo-controlled trials (1728 men, mean age 77) of testosterone therapy on musculoskeletal outcomes
Testosterone (TRT) has a higher evidence score (5.6/10 vs 5.5/10) and wins in 2 of 3 categories.
No known interactions between HCG (Human Chorionic Gonadotropin) and Testosterone (TRT) have been documented in our database. However, always consult a healthcare provider before combining supplements.